OAM
ADPT icon

Oxford Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Oxford Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,395
Closed -$200K – 373
2026
Q1 		$200K Buy
+14,395
New +$229K 0.08% 372

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Oxford Asset Management's ADPT Position: Q2 2026 in Review

Oxford Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 14,395 shares — an estimated $200K sold.

Oxford Asset Management first reported a position in ADPT in Q1 2026 and held it in 1 quarter. The position peaked at $200K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Oxford Asset Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Oxford Asset Management sold 14,395 Adaptive Biotechnologies shares in Q2 2026, an estimated $200K.
  • Oxford Asset Management first reported a position in Adaptive Biotechnologies in Q1 2026 and held it in 1 quarter.
  • Oxford Asset Management's Adaptive Biotechnologies position peaked at $200K in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.